Whereas KRAS alterations and ERBB2 mutations were shown to co-occur in CRC statistically, the percent difference was marginal (55.5% in ERBB2mut vs. 50.5% in ERBB2wt; Supplementary Fig. S8C). This evidence concerns the gene KRAS and colorectal carcinoma.